Tyme Technologies Inc (NASDAQ:TYME) CEO Steve Hoffman sold 51,000 shares of Tyme Technologies stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $1.21, for a total transaction of $61,710.00. Following the completion of the transaction, the chief executive officer now directly owns 26,390,449 shares of the company’s stock, valued at $31,932,443.29. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Steve Hoffman also recently made the following trade(s):
- On Thursday, July 16th, Steve Hoffman sold 51,299 shares of Tyme Technologies stock. The stock was sold at an average price of $1.26, for a total transaction of $64,636.74.
TYME stock opened at $1.19 on Friday. Tyme Technologies Inc has a 12 month low of $0.86 and a 12 month high of $2.04. The company has a 50-day moving average price of $1.29 and a 200 day moving average price of $1.33. The stock has a market cap of $150.67 million, a PE ratio of -6.61 and a beta of 0.97.
Tyme Technologies (NASDAQ:TYME) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. On average, equities research analysts predict that Tyme Technologies Inc will post -0.28 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its position in Tyme Technologies by 2.2% in the 1st quarter. State Street Corp now owns 1,412,561 shares of the company’s stock valued at $1,554,000 after buying an additional 30,640 shares during the period. Geode Capital Management LLC boosted its position in Tyme Technologies by 5.2% in the 1st quarter. Geode Capital Management LLC now owns 781,500 shares of the company’s stock valued at $859,000 after buying an additional 38,310 shares during the period. Nuveen Asset Management LLC boosted its position in Tyme Technologies by 17.8% in the 1st quarter. Nuveen Asset Management LLC now owns 250,741 shares of the company’s stock valued at $276,000 after buying an additional 37,862 shares during the period. UBS Group AG boosted its position in Tyme Technologies by 49.1% in the 4th quarter. UBS Group AG now owns 90,630 shares of the company’s stock valued at $127,000 after buying an additional 29,829 shares during the period. Finally, Pathstone Family Office LLC purchased a new stake in Tyme Technologies in the 1st quarter valued at about $99,000. 11.89% of the stock is owned by institutional investors.
A number of equities analysts recently commented on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Tyme Technologies in a research note on Monday, June 29th. Zacks Investment Research raised shares of Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.50 price target on shares of Tyme Technologies in a research note on Thursday, May 21st.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Featured Article: The role of implied volatility with call option volume
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.